Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 7.080

+3.1%

Nov 24 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	3/5/2007 11:07:40 AM
	Read Replies (1) of 802

>>Introgen to Report Q4 Results - ADVEXIN(R) Filings On Track - Management Will Discuss Operations, Comment Upon Recent Developments Monday March 5, 9:18 am ET AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN - News) announced today that it will host a conference call to discuss its fourth quarter and year end results. During the call, Introgen will also provide updates on its regulatory and clinical developments. Introgen will confirm its guidance for ADVEXIN filings which remain on track and are advancing in both the United States and Europe. In addition, management will comment upon recently published false and misleading internet articles and other developments. The call will be held Thursday, March 8, 2007, at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). The call may be accessed at Introgen's Web site at www.introgen.com. The call may also be accessed by dialing 1-877-616-4476 or 1-706-679-7372. For those unable to listen to the broadcast live, the call will be archived for replay on Introgen's website.<< snip This ought to be one of the most interesting calls of the quarter. Sure hope someone asks about the whereabouts of the PIII for 241. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next